SCHEDULE: Suvretta Capital, Aaron Cowen Disclose 5.6% Stake in 89bio

Suvretta Capital Management, LLC and Aaron Cowen have reported a 5.6% beneficial ownership stake in 89bio, Inc. common stock as of September 30, 2025.

Summary

• Suvretta Capital Management, LLC, Averill Master Fund, Ltd., and Aaron Cowen have filed an Amendment No. 5 to Schedule 13G regarding their beneficial ownership of 89bio, Inc. common stock.
• As of September 30, 2025, Suvretta Capital Management, LLC beneficially owns 8,280,000 shares, representing 5.6% of the class, with shared voting and dispositive power.
• Aaron Cowen also beneficially owns 8,280,000 shares, representing 5.6% of the class, with shared voting and dispositive power, and is identified as the control person for Suvretta Capital Management, LLC.
• Averill Master Fund, Ltd. beneficially owns 7,135,599 shares, representing 4.8% of the class, with shared voting and dispositive power.
• The reporting persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of 89bio, Inc.

Sentiment

Score: 5

Explanation: The filing is a routine Schedule 13G amendment disclosing beneficial ownership stakes by institutional investors and an individual. It explicitly states the holdings are for ordinary course of business and not for influencing control, thus presenting a neutral sentiment regarding the company's strategic direction or immediate operational impact.

Future Outlook

NA

Industry Context

NA

Key Dates

Keywords

89bio, Suvretta Capital Management, Aaron Cowen, Averill Master Fund, beneficial ownership, Schedule 13G, common stock, institutional ownership, investment adviser